Table 3 Summary of previous studies of miR-29s in patients with PD.
From: Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease
Samples from subject Groups (n) | Age at inclusion (years; means ± SD) | Gender Men (%) | HY stage | Duration (years; means ± SD) | Normalizers | Results (relate to miR-29s) | Ref. | |
|---|---|---|---|---|---|---|---|---|
211(serum) | Controls(95) | 67.22 ± 10.72 | 46.3 | — | — | miR-17 | ||
IPD(95) | 67.7 ± 10.39 | 40 | 1–5 | 9.6 (CI4-12) | miR-106a | miR-29a/c ↓ | ||
LRRK2 PD(21) | 61.83 ± 11.64 | 46.3 | — | — | miR-29a/c ↓ | |||
92(PBMCs) | Controls(36/10) | 67 ± 10/67 ± 7 | 39/60 | — | — | |||
L-dopa-treated(36) | 68 ± 11 | 39 | 1–3 | 7 ± 6 | RNU24 | miR-29a ↑ | ||
Untreated (10) | 68 ± 7 | 60 | 1–2.5 | 4 ± 3 | Z30 | miR-29a/b — | ||
23(blood) | Controls(8) | 67 ± 8 | — | — | ||||
Untreated(8) | 66 ± 6.7 | 50 | 1–2 | 3 ± 2.6 | NA | miR-29a ↓ | ||
EOPD(7) | 45 ± 8.7 | 1–3 | 7.2 ± 6.6 | miR-29a — | ||||
Treated(4)@ | — | — | — | miR-29a ↓ | ||||
32(PBMCs) | Controls(13) | 64.38 ± 5.92 | 38.5 | — | — | Microarrays | ||
PD(19) | 65.11 ± 4.37 | 52.6 | 1–5 | 8.7 ± 5.1 | miR-29b/c ↓ |
